Australia markets closed
  • ALL ORDS

    6,943.00
    -57.60 (-0.82%)
     
  • ASX 200

    6,710.80
    -49.90 (-0.74%)
     
  • AUD/USD

    0.7680
    -0.0039 (-0.51%)
     
  • OIL

    66.28
    +2.45 (+3.84%)
     
  • GOLD

    1,698.20
    -2.50 (-0.15%)
     
  • BTC-AUD

    64,204.38
    +880.34 (+1.39%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • AUD/EUR

    0.6443
    0.0000 (0.00%)
     
  • AUD/NZD

    1.0714
    -0.0023 (-0.21%)
     
  • NZX 50

    12,180.25
    -44.25 (-0.36%)
     
  • NASDAQ

    12,668.51
    +204.51 (+1.64%)
     
  • FTSE

    6,630.52
    -20.36 (-0.31%)
     
  • Dow Jones

    31,496.30
    +572.16 (+1.85%)
     
  • DAX

    13,920.69
    -135.65 (-0.97%)
     
  • Hang Seng

    29,098.29
    -138.50 (-0.47%)
     
  • NIKKEI 225

    28,864.32
    -65.78 (-0.23%)
     

Global Urinary Tract Infection Treatment Market Trajectory & Analytics Report 2020-2027 - ResearchAndMarkets.com

·5-min read

The "Urinary Tract Infection Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Urinary Tract Infection Treatment Market to Reach US$11.3 Billion by the Year 2027

Amid the COVID-19 crisis, the global market for Urinary Tract Infection Treatment estimated at US$8.9 Billion in the year 2020, is projected to reach a revised size of US$11.3 Billion by 2027, growing at a CAGR of 3.5% over the analysis period 2020-2027.

Quinolones, one of the segments analyzed in the report, is projected to grow at a 3.4% CAGR to reach US$4.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Aminoglycosides segment is readjusted to a revised 3.7% CAGR for the next 7-year period. This segment currently accounts for a 17% share of the global Urinary Tract Infection Treatment market.

The U. S. Accounts for Over 28.9% of Global Market Size in 2020, While China is Forecast to Grow at a 5.8% CAGR for the Period of 2020-2027

The Urinary Tract Infection Treatment market in the U. S. is estimated at US$2.6 Billion in the year 2020. The country currently accounts for a 28.88% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$1.9 Billion in the year 2027 trailing a CAGR of 5.8% through 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 2.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR while Rest of European market (as defined in the study) will reach US$1.9 Billion by the year 2027.

B-lactam Segment Corners a 11.9% Share in 2020

In the global B-lactam segment, USA, Canada, Japan, China and Europe will drive the 2.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$802.7 Million in the year 2020 will reach a projected size of US$978.4 Million by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.5 Billion by the year 2027, while Latin America will expand at a 3.2% CAGR through the analysis period. We bring years of research experience to this 7th edition of our report.

The report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Impact of Covid-19 and a Looming Global Recession

  • Global Competitor Market Shares

  • Urinary Tract Infection Treatment Competitor Market Share Scenario Worldwide (in %): 2018E

2. FOCUS ON SELECT PLAYERS

  • Allergan PLC

  • AstraZeneca PLC

  • Bayer AG

  • Johnson & Johnson

  • Lipella Pharmaceuticals Inc.

  • Merck & Co., Inc.

  • MerLion Pharmaceuticals GmbH

  • Mylan Pharmaceutical Pvt. Ltd.

  • Novartis AG

  • Novo Nordisk A/S

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

  • Urigen Pharmaceuticals, Inc.

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

  • World 15-Year Perspective for Urinary Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2018 & 2027

  • World 15-Year Perspective for Quinolones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027

  • World 15-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027

  • World 15-Year Perspective for B-lactam by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027

  • World 15-Year Perspective for Azoles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027

  • World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

  • Market Facts & Figures

  • Urinary Tract Infection Treatment Market Share (in %) by Company: 2018 & 2027

  • Market Analytics

  • Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, B-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Billion for the Years 2018 through 2027

  • Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, B-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2017

  • 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, B-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027

IV. COMPETITION

  • Total Companies Profiled: 36

For more information about this report visit https://www.researchandmarkets.com/r/fdyz4z

View source version on businesswire.com: https://www.businesswire.com/news/home/20210118005462/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900